Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Corrigendum: Clinical efficacy, safety and tolerability of a new subcutaneous immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the treatment of patients with primary immunodeficiencies.
Kobayashi RH, Gupta S, Melamed I, Mandujano JF, Kobayashi AL, Ritchie B, Geng B, Atkinson TP, Rehman S, Turpel-Kantor E, Litzman J. Kobayashi RH, et al. Among authors: kobayashi al. Front Immunol. 2022 Dec 20;13:1110388. doi: 10.3389/fimmu.2022.1110388. eCollection 2022. Front Immunol. 2022. PMID: 36605207 Free PMC article.
Topical nasal sprays: treatment of allergic rhinitis.
Kobayashi RH, Kiechel F 3rd, Kobayashi AL, Mellion MB. Kobayashi RH, et al. Among authors: kobayashi al. Am Fam Physician. 1994 Jul;50(1):151-7, 161-2. Am Fam Physician. 1994. PMID: 7517094 Review.
Efficacy, Safety, and Pharmacokinetics of a New 10 % Liquid Intravenous Immunoglobulin Containing High Titer Neutralizing Antibody to RSV and Other Respiratory Viruses in Subjects with Primary Immunodeficiency Disease.
Wasserman RL, Lumry W, Harris J 3rd, Levy R, Stein M, Forbes L, Cunningham-Rundles C, Melamed I, Kobayashi AL, Du W, Kobayashi R. Wasserman RL, et al. Among authors: kobayashi al. J Clin Immunol. 2016 Aug;36(6):590-9. doi: 10.1007/s10875-016-0308-z. Epub 2016 Jun 20. J Clin Immunol. 2016. PMID: 27324887 Free PMC article. Clinical Trial.
Efficacy and Safety of Human Intravenous Immunoglobulin 10% (Panzyga®) in Patients with Primary Immunodeficiency Diseases: a Two-Stage, Multicenter, Prospective, Open-Label Study.
Borte M, Melamed IR, Pulka G, Pyringer B, Knutsen AP, Ochs HD, Kobayashi RH, Kobayashi AL, Gupta S, Strach M, Smits W, Pituch-Noworolska A, Moy JN. Borte M, et al. Among authors: kobayashi al. J Clin Immunol. 2017 Aug;37(6):603-612. doi: 10.1007/s10875-017-0424-4. Epub 2017 Jul 29. J Clin Immunol. 2017. PMID: 28755067 Free PMC article. Clinical Trial.
Pharmacokinetics of a novel human intravenous immunoglobulin 10% in patients with primary immunodeficiency diseases: Analysis of a phase III, multicentre, prospective, open-label study.
Melamed IR, Borte M, Trawnicek L, Kobayashi AL, Kobayashi RH, Knutsen A, Gupta S, Smits W, Pituch-Noworolska A, Strach M, Pulka G, Ochs HD, Moy JN. Melamed IR, et al. Among authors: kobayashi al. Eur J Pharm Sci. 2018 Jun 15;118:80-86. doi: 10.1016/j.ejps.2018.03.007. Epub 2018 Mar 6. Eur J Pharm Sci. 2018. PMID: 29522908 Free article. Clinical Trial.
Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies.
Kobayashi RH, Gupta S, Melamed I, Mandujano JF, Kobayashi AL, Ritchie B, Geng B, Atkinson TP, Rehman S, Turpel-Kantor E, Litzman J. Kobayashi RH, et al. Among authors: kobayashi al. Front Immunol. 2019 Feb 4;10:40. doi: 10.3389/fimmu.2019.00040. eCollection 2019. Front Immunol. 2019. PMID: 30778345 Free PMC article.
Evaluation of Intravenous Immunoglobulin in Pediatric Acute-Onset Neuropsychiatric Syndrome.
Melamed I, Kobayashi RH, O'Connor M, Kobayashi AL, Schechterman A, Heffron M, Canterberry S, Miranda H, Rashid N. Melamed I, et al. Among authors: kobayashi al. J Child Adolesc Psychopharmacol. 2021 Mar;31(2):118-128. doi: 10.1089/cap.2020.0100. Epub 2021 Feb 18. J Child Adolesc Psychopharmacol. 2021. PMID: 33601937 Free PMC article. Clinical Trial.
Long-term efficacy, safety, and tolerability of a subcutaneous immunoglobulin 16.5% (cutaquig®) in the treatment of patients with primary immunodeficiencies.
Kobayashi RH, Litzman J, Melamed I, Mandujano JF, Kobayashi AL, Ritchie B, Geng B, Atkinson TP, Rehman S, Höller S, Turpel-Kantor E, Kreuwel H, Speer JC, Gupta S. Kobayashi RH, et al. Among authors: kobayashi al. Clin Exp Immunol. 2022 Dec 15;210(2):91-103. doi: 10.1093/cei/uxac092. Clin Exp Immunol. 2022. PMID: 36208448 Free PMC article.
17 results